2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Related Products

PDF 0.8 MB

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-111540A
    (Rac)-LY-3381916
    		Inhibitor 99.12%
    (Rac)-LY-3381916 ((Rac)-IDO1-IN-5; Example 1) is a racemate of LY-3381916. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
    (Rac)-LY-3381916
  • HY-18770
    IDO-IN-5
    		Inhibitor 99.90%
    IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC50 of 1-10 μM.
    IDO-IN-5
  • HY-18770C
    IDO-IN-8
    		Inhibitor 99.99%
    IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM.
    IDO-IN-8
  • HY-115122
    IDO-IN-12
    		Inhibitor 99.22%
    IDO-IN-12 is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO 2017181849 A1.
    IDO-IN-12
  • HY-112164B
    IACS-8968 S-enantiomer
    		Inhibitor 98.43%
    IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
    IACS-8968 S-enantiomer
  • HY-N2463
    Kushenol E
    		Inhibitor
    Kushenol E is a class of flavonoids isolated from Sophora flavescens and is a non-competitive indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 of 7.7 µM and a Ki of 9.5 µM, has anti-tumor activity.
    Kushenol E
  • HY-N0430
    Coptisine
    		Inhibitor
    Coptisine is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM.
    Coptisine
  • HY-151425
    TDO-IN-1
    		Inhibitor 99.07%
    TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo.
    TDO-IN-1
  • HY-N0110A
    Palmatine
    		Inhibitor
    Palmatine is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine
  • HY-18770A
    IDO-IN-6
    		Inhibitor 99.90%
    IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC50 of <1 μM.
    IDO-IN-6
  • HY-W113615
    4-Phenyl-1H-1,2,3-triazole
    		Inhibitor ≥98.0%
    4-Phenyl-1H-1,2,3-triazole is an IDO1 inhibitor (IC50: 60 μM). 4-Phenyl-1H-1,2,3-triazole can be used for cancer research.
    4-Phenyl-1H-1,2,3-triazole
  • HY-78699
    2-Hydrazinobenzothiazole
    		Inhibitor 99.95%
    2-Hydrazinobenzothiazole is a potent IDO1 inhibitor with an IC50 of 8 μM. 2-hydrazinobenzothiazole interacts with the IDO1 haem through hydrazine. 2-hydrazinobenzothiazole has the potential for immune system related diseases research.
    2-Hydrazinobenzothiazole
  • HY-145332
    IDO1-IN-11
    		Inhibitor
    IDO1-IN-11 is an IDO1 inhibitor with an IC50 value of 0.6 nM.
    IDO1-IN-11
  • HY-112147
    IDO1 and HDAC1 Inhibitor
    		Inhibitor
    IDO1 and HDAC1 Inhibitor (Compound 10) is a dual IDO1 and HDAC1 inhibitor with IC50s of 69.0 nM and 66.5 nM, respectively.
    IDO1 and HDAC1 Inhibitor
  • HY-134583
    IDO1-IN-7
    		Inhibitor
    IDO1-IN-7 is a highly potent and selective indoleamine-2,3-dioxygenase-1 (IDO1) inhibitor, with an IC50 of 6.1 nM in in the cellular assay (SKOV3). IDO1-IN-7 has immunomodulatory effects. IDO1-IN-7 can be used for the research of cancer.
    IDO1-IN-7
  • HY-110387
    IDO-IN-9
    		Inhibitor
    IDO-IN-9 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.
    IDO-IN-9
  • HY-111234
    IDO-IN-11
    		Inhibitor
    IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.
    IDO-IN-11
  • HY-145280A
    IDO1/2-IN-1 hydrochloride
    		Inhibitor
    IDO1/2-IN-1 hydrochloride (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 hydrochloride exhibits antitumor activies. Orally active.
    IDO1/2-IN-1 hydrochloride
  • HY-151978
    ZC0109
    		Inhibitor 99.32%
    ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC50s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.
    ZC0109
  • HY-148173
    NUCC-0223619
    		Inhibitor
    NUCC-0223619 is an IDO1 inhibitor, induce degradation of IDO protein. NUCC-0223619 can be used to synthesis PROTAC.
    NUCC-0223619
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.